Galapagos N.V.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GLPG.AS research report →
About the company
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
- CEO
- Henry O. Gosebruch
- IPO
- 2005
- Employees
- 452
- HQ
- Mechelen, BE
Price Chart
- Market Cap
- $1.70B
- P/E
- 3.48
- P/S
- 1.63
- P/B
- 0.52
- EV/EBITDA
- 4.97
- Div Yield
- 0.00%
- Gross Margin
- 98.01%
- Op Margin
- 36.43%
- Net Margin
- 46.83%
- ROE
- 16.88%
- ROIC
- 11.61%
- Revenue
- $1.11B · 303.50%
- Net Income
- $320.88M · 333.15%
- EPS
- $4.87 · 334.82%
- Op Income
- $469.66M
- FCF YoY
- 47.60%
- 52W High
- $32.74
- 52W Low
- $22.24
- 50D MA
- $26.02
- 200D MA
- $27.50
- Beta
- 0.15
- Avg Volume
- 98.06K
Get TickerSpark's AI analysis on GLPG.AS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our GLPG.AS coverage
Recent articles, reports, and earnings notes.
No research on GLPG.AS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GLPG.AS report →Similar companies
Peers in the same neighborhood.